Welcome to our dedicated page for Eikon Therapeutics news (Ticker: EIKN), a resource for investors and traders seeking the latest updates and insights on Eikon Therapeutics stock.
Eikon Therapeutics reports company news centered on clinical-stage oncology development, financial results, public-company milestones, and capital-structure updates. Recurring developments include progress across EIK1001, EIK1003, and EIK1004, including lung cancer, prostate cancer, breast cancer, ovarian cancer, and advanced solid tumor programs.
The company’s news also covers corporate updates following its Nasdaq listing, shareholder voting matters, clinical or regulatory disclosures, and financial reporting for a late-stage biopharmaceutical issuer that operates through a single drug discovery and clinical development segment.
Eikon Therapeutics (Nasdaq:EIKN) appointed Ma. Fatima (Fama) D. Francisco as an independent director to its Board, effective June 15, 2026. She will also join the Board’s Compensation Committee.
Francisco brings over 35 years of leadership experience from Procter & Gamble and current board roles at HP and Nestle.
Eikon Therapeutics (Nasdaq:EIKN) presented new clinical data at the 2026 ASCO Annual Meeting for EIK1001 in stage 4 NSCLC and EIK1003 in advanced solid tumors.
TeLuRide-005 reported a 63.1% ORR and 90.8% DCR with EIK1001 plus pembrolizumab/chemotherapy. EIK1003 monotherapy and paclitaxel combination showed defined safety profiles and objective responses across multiple tumor types.
Eikon Therapeutics (Nasdaq:EIKN) announced that six full-text abstracts from its lead oncology programs are now available ahead of presentation at the 2026 ASCO Annual Meeting starting May 29, 2026.
Abstracts cover clinical-stage candidates EIK1001, EIK1003, and EIK1005 across multiple advanced solid tumors.
Eikon Therapeutics (Nasdaq:EIKN) reported first quarter 2026 results and clinical progress. The company held $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 and expects this to fund operations into the second half of 2027.
Eikon highlighted advancing oncology programs EIK1001, EIK1003 and EIK1005, multiple Phase 1/2 and Phase 2/3 trials in solid tumors, six accepted ASCO 2026 abstracts, and a Journal of Medicinal Chemistry publication. First-quarter R&D expenses were $70.0 million, G&A expenses $17.3 million, and net loss $83.0 million.
Eikon Therapeutics (Nasdaq: EIKN) reported corporate and clinical updates on March 30, 2026, including a closed upsized IPO raising $381.2 million and a cash, cash equivalents and marketable securities balance of $336.0 million as of December 31, 2025. The company expects cash to fund operations into the second half of 2027.
Clinical progress: completed enrollment in the TeLuRide-005 Phase 2 trial of EIK1001 with data expected in 2H 2026; EIK1003 and EIK1004 Phase 1/2 programs advancing with a cohort start anticipated in 2H 2026; EIK1005 healthy volunteer study completed and patient trial underway. Financials show year-over-year increases in R&D and G&A and a 2025 net loss of $333.6 million.
Eikon Therapeutics (Nasdaq:EIKN) priced an upsized initial public offering of 21,177,600 shares at $18.00 per share, with gross proceeds expected to be approximately $381 million before fees. The underwriters have a 30-day option for an additional 3,176,640 shares.
Shares are expected to begin trading on the Nasdaq Global Select Market on February 5, 2026, with the offering scheduled to close on or about February 6, 2026, subject to customary closing conditions.